润都股份：公司1类创新药盐酸去甲乌药碱注册审评工作正在有序推进

Core Viewpoint - The company is actively progressing with the registration review of its innovative drug, Sodium Dehydroacetic Acid, and will disclose significant updates in accordance with regulatory requirements [1] Group 1: Drug Development and Approval - The registration review of Sodium Dehydroacetic Acid is proceeding in an orderly manner, with the specific progress dependent on the National Medical Products Administration (NMPA) [1] - The company maintains good communication with multiple clinical institutions involved in the research, establishing a solid professional foundation for future commercialization [1] - The company is open to collaborating with experienced and capable large teams for the promotion of this product [1] Group 2: Business Strategy and Operations - The company is actively expanding its overseas sales through localized strategies and is increasing efforts in Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO) businesses [1] - The company is implementing cost reduction and efficiency enhancement measures to address industry competition and operational pressures [1] - The management is committed to protecting shareholder interests and ensuring sustainable operations, with plans to dynamically adjust development strategies based on industry trends and actual business conditions [1]